BCL2 and lymphoma: Moreover, SA-β-gal activity reached much higher levels in ADR-exposed LSD1;bcl2 lymphomas if co-treated with the LSD1 inhibitor 2-PCPA-1a in vitro (Supplementary Fig. 4d), similarly to the high SA-β-gal activity induced by CTX exposure under 2-PCPA-1a co-treatment in vivo (Fig. 4d).